Case 16-2012: A 32-year-old woman with HER2-positive breast cancer

New England Journal of Medicine

Volumn 366, Issue 21, 2012, Pages 2018-2026

  Baselga, José ^a,b   Smith, Barbara Lynn ^a,b   Rafferty, Elizabeth A ^a,b   Bombonati, Alessandro ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; PROGESTERONE RECEPTOR; TAXANE DERIVATIVE; TRASTUZUMAB; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY; TAXOID;

ADULT; ARTICLE; BREAST CARCINOMA; BREAST TUMOR; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER GRADING; CANCER STAGING; CANCER SURVIVAL; CASE REPORT; COMPUTER ASSISTED EMISSION TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; ECHOMAMMOGRAPHY; FEMALE; HISTOPATHOLOGY; HUMAN; IMAGE ENHANCEMENT; IMMUNOHISTOCHEMISTRY; LEUKOCYTE COUNT; LIVER METASTASIS; MASTECTOMY; MEDICAL HISTORY; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; MUTATIONAL ANALYSIS; NEEDLE BIOPSY; NUCLEAR MAGNETIC RESONANCE IMAGING; PALPATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR GROWTH; TUMOR SUPPRESSOR GENE; TUMOR VOLUME; ADJUVANT THERAPY; CHEMISTRY; CLINICAL OBSERVATION; CLINICAL STUDY; DIAGNOSIS; LIVER TUMOR; METASTASIS; PAGET NIPPLE DISEASE; PATHOLOGY;

ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CARBOPLATIN; CARCINOMA, DUCTAL, BREAST; FEMALE; HUMANS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MASTECTOMY; NEOADJUVANT THERAPY; NEOPLASM STAGING; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84861374000     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMcpc1111576     Document Type: Article

References (30)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/ neu oncogene. Science 1987;235:177-82. (Pubitemid 17231334)
2. Baselga J, Tripathy D, Mendelsohn J, et al. Phase II study of weekly intravenous recombinant humanized anti-p185HER2 monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast cancer. J Clin Oncol 1996;14:737-44.
3. Slamon DJ, Leyland-Jones B, Shak S, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783-92. (Pubitemid 32222155)
4. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25:118-45. (Pubitemid 350003059)
5. Dowsett M, Procter M, McCaskill- Stevens W, et al. Disease-free survival according to degree of HER2 amplification for patients treated with adjuvant chemotherapy with or without 1 year of trastuzumab: the HERA Trial. J Clin Oncol 2009;27:2962-9.
6. Cobleigh MA, Vogel CL, Tripathy D, et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2- overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. J Clin Oncol 1999; 17:2639-48. (Pubitemid 29415219)
7. Vogel CL, Cobleigh MA, Tripathy D, et al. Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol 2002;20:719-26. (Pubitemid 34111379)
8. Hudis CA. Trastuzumab - mechanism of action and use in clinical practice. N Engl J Med 2007;357:39-51. (Pubitemid 47026733)
9. Marty M, Cognetti F, Maraninchi D, et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 Study Group. J Clin Oncol 2005;23:4265-74. (Pubitemid 46207001)
10. Pegram MD, Pienkowski T, Northfelt DW, et al. Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2- positive advanced breast cancer. J Natl Cancer Inst 2004;96:759-69. (Pubitemid 38771821)
11. Robert N, Leyland-Jones B, Asmar L, et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786-92. (Pubitemid 46630577)
12. Valero V, Forbes J, Pegram MD, et al. Multicenter phase III randomized trial comparing docetaxel and trastuzumab with docetaxel, carboplatin, and trastuzumab as first-line chemotherapy for patients with HER2-gene-amplified metastatic breast cancer (BCIRG 007 study): two highly active therapeutic regimens. J Clin Oncol 2011;29:149-56.
13. Pegram MD, Lipton A, Hayes DF, et al. Phase II study of receptor-enhanced chemo-sensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol 1998;16:2659-71. (Pubitemid 28363029)
14. Babiera GV, Rao R, Feng L, et al. Effect of primary tumor extirpation in breast cancer patients who present with stage IV disease and an intact primary tumor. Ann Surg Oncol 2006;13:776-82. (Pubitemid 43727360)
15. Cady B, Nathan NR, Michaelson JS, Golshan M, Smith BL. Matched pair analyses of stage IV breast cancer with or without resection of primary breast site. Ann Surg Oncol 2008;15:3384-95.
16. Morrogh M, Park A, Norton L, King TA. Changing indications for surgery in patients with stage IV breast cancer: a current perspective. Cancer 2008;112: 1445-54. (Pubitemid 351441157)
17. Khan SA. Primary tumor resection in stage IV breast cancer: consistent benefit, or consistent bias? Ann Surg Oncol 2007; 14:3285-7. (Pubitemid 350160116)
18. Khan SA, Stewart AK, Morrow M. Does aggressive local therapy improve survival in metastatic breast cancer? Surgery 2002;132:620-6.
19. Fields RC, Jeffe DB, Trinkaus K, et al. Surgical resection of the primary tumor is associated with increased long-term survival in patients with stage IV breast cancer after controlling for site of metastasis. Ann Surg Oncol 2007;14:3345-51. (Pubitemid 350160108)
20. Cobleigh MA, Griem KL, Siziopikou KP. Long term disease-free survival after stopping trastuzumab in trastuzumab-sensitive metastatic breast cancer patients treated with local-regional therapy. J Clin Oncol 2008;Suppl:26:610s. abstract.
21. von Minckwitz G, du Bois A, Schmidt M, et al. Trastuzumab beyond progression in human epidermal growth factor receptor 2-positive advanced breast cancer: a German Breast Group 26/Breast International Group 03-05 study. J Clin Oncol 2009;27:1999-2006.
22. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2- positive advanced breast cancer. N Engl J Med 2006;355:2733-43. [Erratum, N Engl J Med 2007;356:1487.] (Pubitemid 46021510)
23. Blackwell KL, Burstein HJ, Storniolo AM, et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124-30.
24. Burris HA III, Rugo HS, Vukelja SJ, et al. Phase II study of the antibody drug conjugate trastuzumab-DM1 for the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer after prior HER2-directed therapy. J Clin Oncol 2011;29:398-405.
25. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer 2009;9:463-75.
26. Bendell JC, Domchek SM, Burstein HJ, et al. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 2003;97:2972-7. (Pubitemid 36676250)
27. Clayton AJ, Danson S, Jolly S, et al. Incidence of cerebral metastases in patients treated with trastuzumab for metastatic breast cancer. Br J Cancer 2004;91: 639-43. (Pubitemid 39141617)
28. Lai R, Dang CT, Malkin MG, Abrey LE. The risk of central nervous system metastases after trastuzumab therapy in patients with breast carcinoma. Cancer 2004;101:810-6. (Pubitemid 39030939)
29. Niwińska A, Tacikowska M, Murawska M. The effect of early detection of occult brain metastases in HER2-positive breast cancer patients on survival and cause of death. Int J Radiat Oncol Biol Phys 2010;77:1134-9.
30. Wolstenholme V, Hawkins M, Ashley S, Tait D, Ross G. HER2 significance and treatment outcomes after radiotherapy for brain metastases in breast cancer patients. Breast 2008;17:661-5.